Difference between revisions of "Ivosidenib (Tibsovo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 14: | Line 14: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:IDH1 inhibitors]] | [[Category:IDH1 inhibitors]] | ||
Revision as of 22:18, 11 August 2018
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 7/20/2018: Granted FDA approval "for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test."
Also known as
- Code name: AG-120
- Brand name: Tibsovo